Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds
- Conditions
- Breast Cancer
- Interventions
- Other: Phone interview
- Registration Number
- NCT03447886
- Lead Sponsor
- Dana-Farber Cancer Institute
- Brief Summary
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
- Detailed Description
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 17
- Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are "having difficulty paying the bills no matter what they do" to a question about their current household financial situation.18, 19
- report a history of Stage 1-3 breast cancer
- reports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET)
- not in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin
- at least 3 months, but no more than 3 years out of completion of active treatment
- no evidence of recurrent/metastatic disease
- at least 18, but< 45 years of age at diagnosis of first invasive breast cancer
- English or Spanish speaking
- are willing to consent to the interview
- HR- breast cancer and indicate they are not taking ET
- HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET
- Stage 0 (DCIS) breast cancer
- Recurrent or metastatic disease
- Less than 3 months or more than 3 years post-active treatment
- Less than 18 years old or ≥45 years old at diagnosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Quality Of Life Phone interview This study uses qualitative research methods, specifically semi-structured interviews. * This will include moderator guide development, * Phone interviews with breast cancer survivors will be conducted * Qualitative data analysis of the phone interviews will be conducted
- Primary Outcome Measures
Name Time Method Decision-making around endocrine therapy in young women with HR+ breast cancer. 3 months-3 years post active treatment Open ended questions
- Secondary Outcome Measures
Name Time Method Barriers and challenges to endocrine therapy adherence 3 months-3 years post active treatment Open ended questions
Menopausal symptoms 3 months-3 years post active treatment BCPT Symptom Checklist
Social support 3 months-3 years post active treatment Open ended questions
Health behaviors 3 months-3 years post active treatment Open ended questions
Endocrine therapy adherence intervention preferences 3 months-3 years post active treatment Open ended questions
Health literacy 3 months-3 years post active treatment Brief Health Literacy Screener (Chew items)
Trial Locations
- Locations (1)
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States